Article
The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Digestion - 1 Jan 2019
Franck Caspar, Rosania Rosa, Franke Sabine, Haybaeck Johannes, Canbay Ali, Venerito Marino
Abstract excerpt
BACKGROUND: Sorafenib has shown efficacy in patients with imatinib-, sunitinib-, and regorafenib-resistant gastrointestinal stromal tumors (GISTs). No biomarker is currently available for predicting response to sorafenib in patients with GIST. METHODS: We herein report 3 patients with imatinib-, sunitinib-, and regorafenib-resistant metastasized GISTs, who were treated with sorafenib. Besides receptor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.